Who are Dianthus Therapeutics, Inc.'s main suppliers?

Dianthus Therapeutics, Inc. (DNTH) key suppliers include: Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, LGNZZ, LGNZZ, Sanofi and 3 more. View the full supplier network at chainsifter.com/chain/DNTH.

Who are Dianthus Therapeutics, Inc.'s major customers?

Dianthus Therapeutics, Inc. (DNTH) key customers include: TENACIA, ZENAS, Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, LGNZZ and 1 more. View the full customer network at chainsifter.com/chain/DNTH.

What sector is Dianthus Therapeutics, Inc. in?

Dianthus Therapeutics, Inc. (DNTH) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

DNTH Supply Chain: Dianthus Therapeutics, Inc. Supplier List & 17 Relationships

8Suppliers

6Customers

3Debt Items

20Related Chains

Dianthus Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Act…
LGND	Ligand Pharmaceuticals Incorporated	72%	tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGNZZ	LGNZZ	72%	tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGNZZ	LGNZZ	72%	Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing acti…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from SNYN…
SNYNF	Sanofi	72%	. Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal inf…
ZBIO	Zenas BioPharma, Inc.	72%	. Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal inf…
ZBIO	Zenas BioPharma, Inc.	72%	Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from ZBIO g…

Dianthus Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
TENACIA	TENACIA	92%	Pursuant to the Tenacia Option, if Tenacia exercises the option and pays the Company the option exercise fee related to the second antibody sequence, the Company will grant Tenacia an exclusive licen…
ZENAS	ZENAS	90%	The Company assessed the Zenas Agreements in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), and concluded that it represented a contract with a customer and was within the …
LGND	Ligand Pharmaceuticals Incorporated	72%	tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activ…
LGNZZ	LGNZZ	72%	tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGNZZ	LGNZZ	72%	Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing acti…

Dianthus Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
DNTH-DEBT-9107	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.
DNTH-DEBT-9106	Warrants outstanding: 0.001	90%	xbrl warrant detail from xbrl 2025-12-31.
DNTH-DEBT	Debt stack $1.4M	90%	Market cache reports total debt of $1.4M.

Dianthus Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
DNTH-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 243 tracked holders.

Dianthus Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CLYM	Climb Bio, Inc.	100.00	2
LGNZZ	LIGAND PHARMACEUTICALS INC	100.00	1	['customer', 'supplier']
AZN	AstraZeneca PLC	100.00	2
LGND	Ligand Pharmaceuticals Incorporated	100.00	1	['customer', 'supplier']
BHC	Bausch Health Companies Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
BMYMP	Bristol-Myers Squibb Co	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2
NUVB	Nuvation Bio Inc.	100.00	2
SNYNF	Sanofi	100.00	2	['supplier']
LLY	Eli Lilly and Company	100.00	2
VRDN	Viridian Therapeutics, Inc.	100.00	2
XNCR	Xencor, Inc.	100.00	2
ZENAS	ZENAS	60.75	1	['receiving']
LONA	LeonaBio, Inc.	50.00	2
OABIW	OmniAb, Inc.	50.00	2
SGMO	Sangamo Therapeutics, Inc.	50.00	2
ELUT	Elutia Inc.	50.00	2
PLX	Protalix BioTherapeutics, Inc.	50.00	2
PVLA	Palvella Therapeutics, Inc.	50.00	2

Dianthus Therapeutics, Inc. Supply Chain